Raymond James Keeps Wesport Innovations (WPRT) at Market Perform; Same Old Story, Different Quarter
Get Alerts WPRT Hot Sheet
Price: $1.87 +2.19%
Rating Summary:
8 Buy, 13 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 11 | New: 27
Rating Summary:
8 Buy, 13 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 11 | New: 27
Join SI Premium – FREE
Raymond James is maintaining its Market Perform rating on Westport Innovations (Nasdaq: WPRT) following Q2 results and guidance.
Analyst Pavel Molchanov commented,
On lowered guidance (FY13 revs of $160 - $180 million, from $180 - $200 million prior), Molchanov notes that management commented on incentive delay in Sweden again, also alluding to customer preferences in favor of the CWI ISX12 G engine versus the Westport 15L.
For an analyst ratings summary and ratings history on Westport Innovations click here. For more ratings news on Westport Innovations click here.
Shares of Westport Innovations closed at $31.87 yesterday.
Analyst Pavel Molchanov commented,
The combination of historically high oil prices and cheap North American natural gas is driving sustained expansion of natural gas fuels in the domestic market – as has long been the case overseas. Hardware providers such as Westport play a key role in this trend. The attractive economics – even without significant policy support – and an expanding range of engine models should propel Westport’s sales steadily higher.
On lowered guidance (FY13 revs of $160 - $180 million, from $180 - $200 million prior), Molchanov notes that management commented on incentive delay in Sweden again, also alluding to customer preferences in favor of the CWI ISX12 G engine versus the Westport 15L.
For an analyst ratings summary and ratings history on Westport Innovations click here. For more ratings news on Westport Innovations click here.
Shares of Westport Innovations closed at $31.87 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James on Dianthus Therapeutics (DNTH) Amid 8% Gain: 'Incrementally More Bullish On The CIDP Program (again)'
- Gartner (IT) PT Lowered to $164 at UBS on Q2 Outlook
- The Lovesac Co. (LOVE) PT Raised to $20 at DA Davidson Following Q1 Results
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewRelated Entities
Raymond JamesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share